- Real-time PCR-based test enables high-throughput reliable detection of most prevalent respiratory infections, including COVID-19
- One single test determines the virus responsible for patient symptoms, guiding treatment decisions and rapid isolation strategy if required
FINLAND, Espoo, March 1st, 2021 – Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.
These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The See poster